Kleanthis G. Xanthopoulos, President and CEO at Regulus Therapeutics Inc. (RGLS), sold 89,230 shares at $20.81 ($1.8M) on 2015-03-05, disclosed to the SEC on 2015-03-05.
Scheduled sale ($1.8M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.06 | 65,614 | $1.3M | 72.8% |
| 2 | $20.81 | 23,616 | $491K | 27.2% |
| Total | $20.26 avg | 89,230 | $1.8M | 100% |
| Filing → |
| RGLS | SELL | 2015-03-03 | $1K | — | Filing → |
| RGLS | SELL | 2015-02-03 | $112K | — | Filing → |
| RGLS | SELL | 2015-01-30 | $2.6M | — | Filing → |